Genmab A/S (OTCMKTS:GNMSF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.
According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “
Genmab A/S (GNMSF) opened at 218.00 on Friday. The company has a 50-day moving average price of $218.51 and a 200-day moving average price of $204.01. Genmab A/S has a one year low of $158.25 and a one year high of $225.50. The stock has a market cap of $13.26 billion, a P/E ratio of 62.82 and a beta of 1.08.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.